University of Pittsburgh Cancer Institute

Serum Biomarkers for Colon Cancer

Objective

Develop and validate nuclear matrix proteins as biomarkers for early detection of colon cancer.

Program Description

An integrated multi−disciplinary approach will be used to identify biomarkers for colorectal cancer. The team includes basic cancer researchers and clinicians supported by faculty with expertise in biostatistics/bioinformatics.

Specific Aims

- Characterize, evaluate, and validate a set of unique nuclear matrix proteins (NMPs) which are expressed in colorectal cancer.
- Undertake an extensive Phase 1 and 2 validation study to assess the performance of the NMP biomarker, CC2, for serum−based early detection of colorectal cancer.
- Characterize and evaluate other NMPs, with varying spectrums of expression in pre−malignant (adenomas) and malignant tissue, as potential biomarkers of early disease and/or risk.

Contact Information

Bigbee, William

University Of Pittsburgh Cancer Institute
> 305 Iroquois Bldg.
200 Lothrop St.
> Pittsburgh, PA 15213
Tel: (412) 967−6534
> Fax: (412) 967−6576
Email: bigbeewl@msx.upmc.edu